Safotibant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSafotibant
Drug Alias Namesafotibantum沙福替班沙替班特FOV-2304
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B1 receptor antagonists
TargetsBradykinin B1 receptor
Therapy Area/IndicationsDiabetic macular oedema
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[10
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFovea Pharmaceuticals Sa
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedema

Other Information

ATC CodeN/A
Related LinksN/A